We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Prudent Investors are Buying Aflac (AFL) Shares Now
Read MoreHide Full Article
Aflac Incorporated (AFL - Free Report) is well-poised to grow on the back of higher sales, cost-curbing measures, growing strength in the domestic market and an expanding product suite. The high floating rate income will also continue to aid its investment income.
Outperformer & Zacks Rank
Over the past year, shares of Aflac have gained 18.3%, outperforming the industry’s 13.2% rise. Headquartered in Columbus, GA, AFL operates as a supplemental health and life insurance products provider. It has strong footprints in the United States and Japan. The company has a market cap of $45.5 billion.
Courtesy of solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment.
Let’s delve deeper.
The Zacks Consensus Estimate for AFL’s current-year earnings is pegged at $5.92 per share, which has witnessed six upward estimate revisions in the past 30 days against none in the opposite direction. The estimate indicates 11.1% year-over-year growth. Aflac beat on earnings in all the last four quarters, the average being 7.8%.
The consensus mark for current-year revenues is $18.3 billion. Aflac anticipates improved sales within its Aflac Japan segment this year, buoyed by product launches, product updates and Japan Post performance.
Improving productivity, contributions from platforms like network dental and vision and group life, and disability are likely to drive the U.S. business’ sales going forward. In the last reported quarter, Aflac U.S. sales of $324 million grew 6.4% year over year.
The company’s expense ratio is expected to improve significantly in 2023, dragging the combined ratio down below the year-ago level. Our estimate suggests the combined ratio will stay below 70% in 2023, indicating an improvement from last year’s 74.6%, which will aid its margins. Its costs saving initiatives are expected to drive bottom-line growth. Maintaining a more agile workforce will likely increase AFL’s efficiency over the medium to long term.
Aflac’s balance sheet strength enables the company to take shareholder value boosting measures. It has solid cash and cash equivalents of $4.7 billion as of Jun 30, 2023, and expects debt maturities of $1.3 billion over the next five years. In the first half of this year, it bought back shares worth $1.4 billion. AFL had 95.8 million shares left for buyback as of Jun 30, 2023.
A Risk
However, there is a factor that investors should keep a careful eye on.
Aflac’s net cash from operations declined 15.2% in 2021, 23.2% in 2022 and 38.6% in the first half of 2023. The continuation of this trend can impact future operations. Nevertheless, we believe that a systematic and strategic plan of action will drive growth in the long term.
The consensus mark for Employers Holdings’ current year earnings indicates a 10.2% year-over-year increase. Furthermore, the consensus estimate for EIG’s revenues in 2023 suggests 20.5% year-over-year growth.
The Zacks Consensus Estimate for Trupanion’s current year earnings has improved 9.2% in the past 30 days. Also, the consensus mark for TRUP’s revenues in 2023 suggests 19.2% year-over-year growth.
The Zacks Consensus Estimate for Aegon’s current year earnings has improved 16.7% in the Past 30 days. During this period, AEG has witnessed one upward estimate revision against none in the opposite direction.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Prudent Investors are Buying Aflac (AFL) Shares Now
Aflac Incorporated (AFL - Free Report) is well-poised to grow on the back of higher sales, cost-curbing measures, growing strength in the domestic market and an expanding product suite. The high floating rate income will also continue to aid its investment income.
Outperformer & Zacks Rank
Over the past year, shares of Aflac have gained 18.3%, outperforming the industry’s 13.2% rise. Headquartered in Columbus, GA, AFL operates as a supplemental health and life insurance products provider. It has strong footprints in the United States and Japan. The company has a market cap of $45.5 billion.
Courtesy of solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment.
Let’s delve deeper.
The Zacks Consensus Estimate for AFL’s current-year earnings is pegged at $5.92 per share, which has witnessed six upward estimate revisions in the past 30 days against none in the opposite direction. The estimate indicates 11.1% year-over-year growth. Aflac beat on earnings in all the last four quarters, the average being 7.8%.
Aflac Incorporated Price and EPS Surprise
Aflac Incorporated price-eps-surprise | Aflac Incorporated Quote
The consensus mark for current-year revenues is $18.3 billion. Aflac anticipates improved sales within its Aflac Japan segment this year, buoyed by product launches, product updates and Japan Post performance.
Improving productivity, contributions from platforms like network dental and vision and group life, and disability are likely to drive the U.S. business’ sales going forward. In the last reported quarter, Aflac U.S. sales of $324 million grew 6.4% year over year.
The company’s expense ratio is expected to improve significantly in 2023, dragging the combined ratio down below the year-ago level. Our estimate suggests the combined ratio will stay below 70% in 2023, indicating an improvement from last year’s 74.6%, which will aid its margins. Its costs saving initiatives are expected to drive bottom-line growth. Maintaining a more agile workforce will likely increase AFL’s efficiency over the medium to long term.
Aflac’s balance sheet strength enables the company to take shareholder value boosting measures. It has solid cash and cash equivalents of $4.7 billion as of Jun 30, 2023, and expects debt maturities of $1.3 billion over the next five years. In the first half of this year, it bought back shares worth $1.4 billion. AFL had 95.8 million shares left for buyback as of Jun 30, 2023.
A Risk
However, there is a factor that investors should keep a careful eye on.
Aflac’s net cash from operations declined 15.2% in 2021, 23.2% in 2022 and 38.6% in the first half of 2023. The continuation of this trend can impact future operations. Nevertheless, we believe that a systematic and strategic plan of action will drive growth in the long term.
Other Key Picks
Some other top-ranked stocks in the broader finance space are Employers Holdings, Inc. (EIG - Free Report) , Trupanion, Inc. (TRUP - Free Report) and Aegon N.V. (AEG - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The consensus mark for Employers Holdings’ current year earnings indicates a 10.2% year-over-year increase. Furthermore, the consensus estimate for EIG’s revenues in 2023 suggests 20.5% year-over-year growth.
The Zacks Consensus Estimate for Trupanion’s current year earnings has improved 9.2% in the past 30 days. Also, the consensus mark for TRUP’s revenues in 2023 suggests 19.2% year-over-year growth.
The Zacks Consensus Estimate for Aegon’s current year earnings has improved 16.7% in the Past 30 days. During this period, AEG has witnessed one upward estimate revision against none in the opposite direction.